Trial Profile

A First-In-Human (FIH) Study of Inhibitory Interneurons (NRTX- 1001) in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (MTLE)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 24 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

18 Jun 2025 According to Neurona Therapeutics media release, the company plans to present extended durability data from the first ten unilateral MTLE patients treated with low (Cohort 1) and high (Cohort 2) doses of NRTX-1001, along with new results from the eight additional patients who were enrolled in the unilateral MTLE expansion cohorts will be presented at the American Epilepsy Societys Annual Meeting in December 2025.
18 Jun 2025 Results presented in a Neurona Therapeutics Media Release.
18 Jun 2025 Preliminary efficacy and safety data from its ongoing Phase 1/2 trial in unilateral MTLE, most recently presented at the 2025 American Academy of Neurology (AAN) Annual Meeting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com